Elie Naddaf
Overview
Explore the profile of Elie Naddaf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
702
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naddaf E, Skolka M, Prokop L, Dimachkie M, Hogrel J, Benveniste O, et al.
Rheumatology (Oxford)
. 2025 Mar;
PMID: 40085004
Objectives: Inclusion body myositis (IBM) is characterized by slowly progressive muscle weakness making it challenging to detect weakness changes during a clinical trial. Trial participants receiving placebo may behave differently...
2.
Distinct Cytokine and Cytokine Receptor Expression Patterns Characterize Different Forms of Myositis
Kirou R, Pinal-Fernandez I, Casal-Dominguez M, Pak K, Preusse C, Dari D, et al.
medRxiv
. 2025 Mar;
PMID: 40034760
Objective: Myositis is a heterogeneous family of inflammatory myopathies. We sought to define the differential expression of cytokines, cytokine receptors, and immune checkpoint genes in muscle biopsies from patients with...
3.
Martinez-Thompson J, Mazurek K, Parra Cantu C, Naddaf E, Gogineni V, Botha H, et al.
Brain
. 2025 Jan;
PMID: 39820267
Nerve conduction F-wave studies contain critical information about subclinical motor dysfunction which may be used to diagnose patients with amyotrophic lateral sclerosis (ALS). However, F-wave responses are highly variable in...
4.
Naddaf E, Nguyen T, Watzlawik J, Gao H, Hou X, Fiesel F, et al.
J Cachexia Sarcopenia Muscle
. 2024 Dec;
16(1):e13672.
PMID: 39723571
Background: Inclusion body myositis (IBM) is the most prevalent muscle disease in adults for which no current treatment exists. The pathogenesis of IBM remains poorly defined. In this study, we...
5.
Pinto M, Warrington K, Soontrapa P, Koster M, Naddaf E
Neurology
. 2024 Nov;
103(12):e210141.
PMID: 39586051
Background And Objectives: Peripheral neuropathy is a common manifestation of systemic and nonsystemic vasculitides; however, there is limited literature on vasculitic myopathy. We aim to describe the clinical, laboratory, and...
6.
Paul P, Campbell G, Zekeridou A, Mauermann M, Naddaf E
Mayo Clin Proc
. 2024 Aug;
PMID: 39093265
With the lack of distinctive features or diagnostic biomarkers, peripheral neuropathy in patients with excessive alcohol consumption is often misdiagnosed as alcohol-related neuropathy, influenced by underlying implicit and explicit bias...
7.
Essouma M, de Araujo D, Day J, Conticini E, Riopel M, Elias A, et al.
Rheumatol Int
. 2024 Jul;
44(11):2403-2409.
PMID: 38976028
Currently, standardized magnetic resonance imaging (MRI) scoring systems and protocols for assessment of idiopathic inflammatory myopathies (IIMs) in children and adults are lacking. Therefore, we will perform a scoping review...
8.
Naddaf E, Nguyen T, Watzlawik J, Gao H, Hou X, Fiesel F, et al.
medRxiv
. 2024 Jul;
PMID: 38947067
Background: Inclusion body myositis (IBM) is the most prevalent muscle disease in adults for which no current treatment exists. The pathogenesis of IBM remains poorly defined. Inflammation and mitochondrial dysfunction...
9.
Pinal-Fernandez I, Munoz-Braceras S, Casal-Dominguez M, Pak K, Torres-Ruiz J, Musai J, et al.
Ann Rheum Dis
. 2024 Jun;
83(11):1549-1560.
PMID: 38902010
Objectives: Autoantibodies targeting intracellular proteins are common in various autoimmune diseases. In the context of myositis, the pathologic significance of these autoantibodies has been questioned due to the assumption that...
10.
Shammas I, Alhammad R, Naddaf E
Neurology
. 2024 Apr;
102(10):e209477.
PMID: 38657199
No abstract available.